Literature DB >> 174804

Peptide hormones as tumor markers.

J L Vaitukaitis.   

Abstract

Ectopic production and secretion of hormones by a wide variety of tumors were initially recognized by signs and symptoms of excess circulating biologically active hormone. With the development of more sophisticated and sensitive techniques, it has become apparent that not all tumors secrete biologically active hormones. Some altered forms of polypeptide hormones may be in very high concentrations immunologically but be inactive biologically. On the other hand, polypeptide hormones may circulate at concentrations too low to induce clinical signs and symptoms. Consequently, new ectopic humoral syndromes have been recognized and the incidence of previously described syndromes has become considerably greater than previously recognized. Every hormone known to be normally secreted by endocrine organs or the placenta has been documented to be secreted ectopically by a wide variety of tumors. Moreover, several of those hormones may be used as biochemical markers of malignancy for both screening and monitoring of patients with documented or suspected tumors.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 174804     DOI: 10.1002/1097-0142(197601)37:1+<567::aid-cncr2820370722>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

Review 1.  Cell differentiation and the biological significance of inappropriate tumour products.

Authors:  M L Ellison
Journal:  Proc R Soc Med       Date:  1977-12

Review 2.  Primary small cell carcinoma of the esophagus with ectopic gastrin production. Report of a case and review of the literature.

Authors:  T Nishimaki; T Suzuki; T Fukuda; K Aizawa; O Tanaka; T Muto
Journal:  Dig Dis Sci       Date:  1993-04       Impact factor: 3.199

3.  Tumour markers in urology: aids in cancer diagnosis and management.

Authors:  B Wahren
Journal:  Urol Res       Date:  1979-06-22

4.  Value of serum calcitonin estimation in clinical oncology.

Authors:  H Mulder; W H Hackeng; J Silberbusch; G J den Ottolander; C van der Meer
Journal:  Br J Cancer       Date:  1981-06       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.